Ilumya (tildrakizumab-asmn) is a biologic medication prescribed to treat moderate to severe plaque psoriasis. Plaque psoriasis is an autoimmune disease that primarily affects the skin. 

This disease occurs when the immune system begins to attack healthy skin cells leading to plaque inflamed scaly patches that form in various locations throughout the body. 

These scaly patches of skin, known as plaques will appear as red or pink patches covered with silvery scales. On dark skin, plaques can appear thicker, ranging from dark brown, purple, or light gray.  

Ilumya stops the body’s excessive immune response by blocking a cytokine known as interleukin-23 (IL-23). IL-23 may be responsible for activation of interleukin-17 (IL-17) and Tumor Necrosis Factor- Alpha (TNF-Alpha).  

IL-17 and TNF help fight of infection and disease, but when they are overproduced, it leads to healthy cells being attacked instead of just the bad intruder cells.  Blocking IL-23 limits the activity of both IL-17 and TNF-Alpha to reduce inflammation and psoriatic lesions.